E. di Tomaso

发表

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

P. Wen, R. Jain, A. Sorensen, 2009, Cancer research.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

C. Gridelli, S. Thongprasert, E. Felip, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

E. di Tomaso, P. Aimone, C. Massacesi, 2016, OncoTargets and therapy.

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.

Jeffrey W. Clark, D. Sahani, A. Fischman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics

Rakesh K Jain, R. Jain, Y. Boucher, 2002, Science.

Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood.

R K Jain, R Jones, R. Jain, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy.

R. Jain, C. Willett, D. Scadden, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Marek Ancukiewicz, Vivek Sindhwani, Onofrio A Catalano, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Tracy T Batchelor, Thomas Benner, A Gregory Sorensen, 2007, Cancer cell.

Occurrence and Biosynthesis of Endogenous Cannabinoid Precursor,N-Arachidonoyl Phosphatidylethanolamine, in Rat Brain

D. Piomelli, E. di Tomaso, H. Cadas, 1997, The Journal of Neuroscience.

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.

R. Jain, A. Sorensen, L. Munn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.

R. Jain, W. Kamoun, S. Plotkin, 2010, Cancer research.

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

M. Campone, A. Manikhas, L. Dirix, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Engineered blood vessel networks connect to host vasculature via wrapping-and-tapping anastomosis.

R. Jain, L. Munn, D. Fukumura, 2011, Blood.

Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients

A. Stemmer-Rachamimov, A. Muzikansky, S. Plotkin, 2013, PloS one.

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Susan M. Chang, W. Yung, M. Prados, 2009, Neuro-oncology.

Differential circulation kinetics during antiangiogenic therapy of four distinct blood cell populations expressing endothelial markers.

R. Jain, C. Willett, D. Scadden, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.

M Ancukiewicz, R K Jain, H D Suit, 2000, Cancer research.

Platelet-derived growth factor receptor-beta in Gorham's disease.

R. Jain, G. Nielsen, T. Delaney, 2006, Nature clinical practice. Oncology.

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

A. Bardia, F. Meric-Bernstam, F. Penault-Llorca, 2016, Breast.

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Thomas Benner, Percy Ivy, Marek Ancukiewicz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.

J. Baselga, D. Demanse, J. Bendell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model.

A Gregory Sorensen, Guangping Dai, Y. R. Kim, 2010, Neuro-oncology.

Establishment and characterization of a human cell line from paediatric cerebellar glioblastoma multiforme

A. Hui, N. M. Hjelm, P. Lam, 2000, Neuropathology and applied neurobiology.

Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors

R. B. Campbell, R K Jain, S Ramanujan, 2001, Proceedings of the National Academy of Sciences of the United States of America.

LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis.

R. Jain, Y. Boucher, T. Padera, 2001, Cancer research.

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Norikazu Masuda, Stephen Chia, Mark Clemons, 2017, The Lancet. Oncology.

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

C. Schnell, R. Finn, D. Slamon, 2014, Clinical Cancer Research.

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Guy Jerusalem, Cristina Saura, J. Baselga, 2014, Clinical Cancer Research.

Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme.

N M Hjelm, M. Roussel, N. M. Hjelm, 2000, British journal of neurosurgery.

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

W. Sellers, G. Caponigro, Alice T. Loo, 2018, Oncotarget.

Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7.

David A. Orlando, J. Hodgson, J. Carulli, 2019, Cancer research.

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

Lei Xu, Dai Fukumura, M. F. Booth, 2004, Cancer cell.

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.

R. Jain, A. Sorensen, A. Stemmer-Rachamimov, 2009, The New England journal of medicine.

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.

Ricky T. Tong, Jeffrey W. Clark, D. Sahani, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.

Jeffrey W. Clark, R. Jain, R. Bentley, 2010, The oncologist.

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.

Tracy T Batchelor, A Gregory Sorensen, Matija Snuderl, 2011, Cancer research.

Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value

Jeffrey W. Clark, R. Jain, C. Fuchs, 2010, Clinical Cancer Research.

A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

G. Mills, L. Cantley, R. Bronson, 2014, Cancer research.

p53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosis

S. Korsmeyer, R. Jain, T. Jacks, 2009, Science.

Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts.

R. Jain, D. Hicklin, D. Fukumura, 2003, Cancer research.

Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications.

Dai Fukumura, Tohru Hoshida, Rakesh K Jain, 2006, Cancer research.

Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia

M. McKeown, C. Fiore, E. di Tomaso, 2018, Haematologica.

Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.

R. Jain, I. Garkavtsev, M. Klagsbrun, 2012, Neoplasia.

Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor

P. Lollini, M. Iezzi, P. Nanni, 2012, PloS one.

PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment

Rakesh K. Jain, Lance L. Munn, Daniel Fuja, 2009, PloS one.

Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers.

Rakesh K Jain, R. Jain, L. Munn, 2005, Cancer research.

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

Jeffrey W. Clark, R. Jain, R. Bentley, 2009, Cancer research.

Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.

R. Jain, Y. Boucher, C. Willett, 2006, Seminars in oncology.

Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.

E. Giang, F. Paris, S. Maira, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.

Marek Ancukiewicz, Rakesh K Jain, R. Jain, 2011, Clinical ovarian cancer and other gynecologic malignancies.

Angiogenesis in brain tumours

A. Gregory Sorensen, Rakesh K. Jain, Tracy T. Batchelor, 2007, Nature Reviews Neuroscience.

VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer

R. Jain, A. Sorensen, T. Batchelor, 2009, Nature Reviews Clinical Oncology.

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

E. di Tomaso, P. Aimone, C. Massacesi, 2016, OncoTargets and therapy.

Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value

Jeffrey W. Clark, R. Jain, C. Fuchs, 2010, Clinical Cancer Research.

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

P. Wen, D. Louis, R. Jain, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

M. Ancukiewicz, B. Czito, E. di Tomaso, 2009, Cancer Research.

Photothermal Optical Lock-in Optical Coherence Tomography for in Vivo Imaging References and Links

J. Duker, A. Boccara, J. Izatt, 2022 .

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

M. Ancukiewicz, B. Czito, E. di Tomaso, 2009, Cancer research.